(Public, NASDAQ:ABMD)   Watch this stock  
Find more results for ABMD
-0.72 (-0.36%)
Nov 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 197.01 - 199.75
52 week 103.53 - 200.00
Open 199.70
Vol / Avg. 0.00/377,135.00
Mkt cap 8.76B
P/E 97.83
Div/yield     -
EPS 2.03
Shares 44.22M
Beta 0.23
Inst. own 93%
Jan 24, 2018
Q3 2018 Abiomed Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Oct 30, 2017
Abiomed Inc Investor Event at Transcatheter Cardiovascular Therapeutics (TCT) Conference
Oct 26, 2017
Q2 2018 Abiomed Inc Earnings Release
Oct 26, 2017
Q2 2018 Abiomed Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin 18.45% 11.70%
Operating margin 23.89% 20.24%
EBITD margin - 21.63%
Return on average assets 14.59% 10.70%
Return on average equity 16.77% 12.70%
Employees 908 -
CDP Score - -


DANVERS, MA 01923-2575
United States - Map
+1-978-7775410 (Phone)
+1-978-7778411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Officers and directors

Michael R. Minogue Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ian McLeod Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
Bio & Compensation  - Reuters
David M. Weber Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
William J. Bolt Senior Vice President, Global Quality, Regulatory and Clinical Operations
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew J. Greenfield Vice President, General Manager - Global Marketing
Age: 44
Bio & Compensation  - Reuters
Michael G. Howley Vice President, General Manager - Global Sales and Marketing
Age: 53
Bio & Compensation  - Reuters
Dorothy E. Puhy Lead Independent Director
Age: 65
Bio & Compensation  - Reuters
Jeannine M. Rivet Independent Director
Age: 69
Bio & Compensation  - Reuters
Eric A. Rose M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Martin P. Sutter Independent Director
Age: 62
Bio & Compensation  - Reuters